Central Nervous Lymphoma

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2022-04-14
Clinical Trial Update: Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma [Phase 2]
Phase 2 trial update for ibrutinib in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma.